



## **Laurence Greenhill, M.D. - Biography**

Dr. Greenhill is Ruane Professor of Psychiatry and Pediatric Psychopharmacology at Columbia University and a Director of the New York State Research Unit of Pediatric Psychopharmacology at the New York State Psychiatric Institute and Attending at the Columbia Presbyterian Medical Center. After obtaining his Bachelor of Arts Degree at Columbia in 1963, and his Medical degree at Albert Einstein College of Medicine, he served a one year internship in Pediatrics at Jacobi Hospital. He then became a research associate working in the NIMH Lab of Psychology with Paul Wender and David Rosenthal at the Clinical Center in Bethesda, Maryland. In 1975, he was awarded an NIMH Research Career Development Award in the psychopharmacology of child disorders. Under the mentorship of Edward Sachar, M.D., he studied the psycho-neuro-endocrinological responses of children with Attention-Deficit / Hyperactivity Disorder (ADHD) to psycho-stimulants. He has published on the effect of stimulant medication upon the growth hormone and prolactin secretion. He continued his career with funded research investigating the dose equivalency and efficacy of sustained release methylphenidate; the efficacy of molindone in the treatment of inpatient children with conduct disorder; familial pathways in offspring of adult suicide attempters; the effects of age on the cardiovascular responses to tricyclic antidepressants, the efficacy of multimodal treatments in school age children with ADHD.

He has served as the principal investigator of several National Institute of Mental Health Grants, including: the Multimodal Treatment Study of Attention Deficit Hyperactivity Disorder (MTA Study), the MTA Follow-Up Study, the Preschool ADHD Treatment Study (PATS Study) of methylphenidate Safety and efficacy in preschool children with ADHD, the PATS Follow-up Study, the NIMH Research Units of Pediatric Psychopharmacology Study (Parts 1 and 2), and the Treatment Study of Adolescent Suicide Attempters (TASA Study). He completed an investigator-initiated R01 NIMH-sponsored grant "Biological Studies in Suicidal Adolescent (BSSA)" which measured central serotonin metabolites in depressed adolescent inpatient suicide attempters, which served as the inspiration for his 5 year TASA Multisite grant. He has served as a principal investigator of 14 pharmaceutical company contracts, including a study the efficacy and safety of transdermal methylphenidate and deprenyl in ADHD, long-duration d-methylphenidate treatment of adults with ADHD, and the use of long-duration Adderall and long-duration methylphenidate (Concerta) in children and adolescents with ADHD.

Dr. Greenhill is the author of over 120 published articles and has edited three books, including a two editions of a monograph on methylphenidate. He serves as the president of the American Academy of Child & Adolescent Psychiatry, and is the past chairman of the AACAP Program Committee and the past chairman of the AACAP Pediatric Psychopharmacology Initiative. He is the senior Editor of ADHD articles for the Journal of Child and Adolescent Psychopharmacology. While working on the NIMH Multimodal Treatment Study of ADHD children (MTA Study), he coordinated the development of its medication manual. He has completed a 4-year term as a reviewer on the NIMH Mental Health Small Business Innovative Research subcommittee. He has served as one of the senior investigators in the New York State Psychiatric Institute's Center for Study of Suicidal Behavior, John Mann, M.D., Director, and as a member of the Principal Research Core of the NIMH Advanced Center for Intervention Services Research at the New York State Psychiatric Institute Intervention Research Center (David Shaffer, M.D., Principal Investigator).

*Dr Greenhill is a featured speaker at "The Many Faces of ADHD: A Window into the Future", CADDRA's 2010 Annual Conference which will be held from November 20-21, "2010, Vancouver, British Columbia*